Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain and touch. This causes a decrease in the production of certain substances that maintain the integrity of the corneal epithelium (the most superficial layer that covers the cornea). As a result, the cornea cannot heal wounds as fast as it should and this could lead to corneal breakdown. This disease is chronic, meaning that it does not resolve quickly, and the treatments commonly used to manage it (such as artificial tears) take a long time to work, which makes it hard to follow doctor's orders. Autologous platelet-rich plasma is a substance that is obtained from the patient's own blood and it may contain those components that are missing in the tears of people with NK. The purpose of this experiment is to find out whether APRP+PFAT is better than APRP alone or PFAT alone in the treatment of NK. Participants will be randomly assigned to one of three groups: one group will start with APRP, other will start with PFAT and another with PFAT+APRP. The participants will receive each treatment for four weeks, and then the subjects will switch groups and use them for four weeks each (12 weeks total). Investigators will evaluate different parameters that will let us know if your condition is improving. These evaluations will be carried out every four weeks from the start to the end of the protocol. In case of intolerance or adverse effects, treatment will be discontinued.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects

NCT03653650

Persistent Epithelial Defect

RECRUITING NA

Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

NCT04820010

Corneal Ulcer Corneal Perforation Corneal Epithelium Defect +1 more

COMPLETED

Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy

NCT00654888

Corneal Disease

COMPLETED NA

Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

NCT05809245

Neurotrophic Corneal Ulcer Neurotrophic Keratitis Cranial Nerve V Diseases

TERMINATED NA

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

NCT06200727

Platelet-rich Fibrin Macular Holes Pterygium +1 more

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neurotrophic keratopathy is characterized by impaired corneal sensitivity that results in a decrease in neurotrophic and epitheliotropic factors that are essential for proper corneal epithelial and ocular surface function. This neurotrophic state halts mitosis and epithelial turnover, which in turn slow down wound healing and lead to epithelial breakdown. Due to the chronicity of this disease, treatment adherence becomes a problem for patients; furthermore, results with conventional treatments such as preservative-free artificial tears are discouraging. Hematopoietic derivatives such as APRP may replace those missing neurotrophic factors and lead to epithelial healing in a faster and more comfortable manner. The objective of this study is to determine if APRP+PFAT is better than autologous platelet-rich plasma (APRP) or preservative-free artificial tears (PFAT) in the treatment of neurotrophic keratopathy. Subjects will be randomly assigned to one of three groups and treatment will be administered for four weeks. After this period, subjects will switch groups and receive the new treatment for four more weeks (cross-over). After this second period is completed, subjects will receive the last treatment for four more weeks. A thorough ophthalmologic evaluation will be performed before starting treatment and every four weeks until completion. Treatment will be discontinued if there are adverse effects or treatment intolerance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurotrophic Keratopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Subjects will be selected based on inclusion and exclusion criteria. A thorough ophthalmologic evaluation will be carried out before starting any treatment (baseline). Subjects will be randomly assigned to one of the treatment groups and receive the corresponding treatment for 4 weeks. At the end of week 4, subjects will switch treatment groups (crossover) and receive the new treatment for 4 more weeks. At the end of week 8, subjects will start the last treatment for 4 more weeks. Ophthalmologic evaluations will be performed every 4 weeks.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

No blinded study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PFAT first

1 eyedrop of PFAT every 2 hours in study eye.

Group Type EXPERIMENTAL

PFAT first

Intervention Type OTHER

Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

APRP first

1 eyedrop of APRP every 2 hours in study eye.

Group Type EXPERIMENTAL

APRP first

Intervention Type OTHER

Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

APRP+PFAT first

1 eyedrop of PFAT and APRP every 2 hours in study eye.

Group Type EXPERIMENTAL

PFAT first

Intervention Type OTHER

Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

APRP first

Intervention Type OTHER

Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PFAT first

Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Intervention Type OTHER

APRP first

Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with:

* Neurotrophic keratopathy diagnosed by esthesiometry (defined as central corneal sensitivity ≤ 3cm using Cochet-Bonnet aesthesiometer).
* Corneal erosions.
* Neurotrophic keratopathy secondary to: diabetes mellitus, herpetic keratitis, microbial keratitis sequelae (bacteria, Acanthamoeba, fungi, herpes), limbal stem cell deficiency, chemical or thermic burn sequelae at least 3 months after the accident, ocular trauma with penetrating wound fixed at least 3 months before the trial, surgery carried out at least 3 month before the trial (including keratoplasty, laser in situ keratomileusis, phacoemulsification cataract surgery, extracapsular cataract extraction), adenoviral keratoconjunctivitis resolved at least 3 months the trial.

Exclusion Criteria

* Patients diagnosed with:

* Other ocular surface pathology presenting with corneal erosions but without corneal hyposensitivity.
* Corneal epithelial defect with or without corneal hyposensitivity.
* Pregnant women, homeless, migrants.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No